This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lane, N E Articles by Rehman, Q Search for Related Content PubMed PubMed Citation Articles by Lane, N E Articles by Rehman, Q Social Bookmarking                   What's this?

Osteoporosis in the rheumatic disease patient

Department of Medicine, University of California, San Francisco, CA, 94143, USAnelane{at}itsa.ucsf.edu

Q Rehman

Department of Medicine, University of California at San Francisco, San Francisco, California, USA

Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.

Key Words: bone loss • rheumatology patients

Lupus, Vol. 11, No. 10, 675-679 (2002)
DOI: 10.1191/0961203302lu261oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?